| Active substance | eculizumab |
| Holder | Alexion |
| Status | closed |
| Indication | patients with refractory generalized myasthenia gravis (rgMG) who completed the study ECU-MG-302 (Open label extension) and, in the opinion and the clinical judgement of the treating physician would continue to benefit from a treatment with Eculizumab (Soliris®) which is not yet commercially available for this indication in Belgium. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 08/12/2022 |